• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Bluejay Diagnostics Inc.

    1/3/24 4:44:42 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care
    Get the next $BJDX alert in real time by email
    SC 13G 1 bjdx0124.txt BJDX 13G 1.03.24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Bluejay Diagnostics, Inc (Name of Issuer) Common Stock (Title of Class of Securities) 095633103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [_] Rule 13d-1(b) [X] Rule 13d-1(c) [_] Rule 13d-1(d) __________ *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). ? CUSIP No. 095633103 1. NAME OF REPORTING PERSONS Sabby Volatility Warrant Master Fund, Ltd. 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) [_] (b) [X] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 177,513 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 177,513 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 177,513 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.99 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO? CUSIP No. 095633103 1. NAME OF REPORTING PERSONS Sabby Management, LLC 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) [_] (b) [X] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware, USA NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 177,513 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 177,513 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 177,513 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.99 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO CUSIP No. 095633103 1. NAME OF REPORTING PERSONS Hal Mintz 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) [_] (b) [X] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION USA NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 177,513 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 177,513 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 177,513 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.99 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN? CUSIP No. 095633103 Item 1. (a). Name of Issuer: Bluejay Diagnostics, Inc (b). Address of issuer's principal executive offices: 360 MASSACHUSETTS AVENUE, SUITE 203 ACTON, MA, 01720 Item 2. (a). Name of person filing: Sabby Volatility Warrant Master Fund, Ltd. Sabby Management, LLC Hal Mintz (b). Address or principal business office or, if none, residence: Sabby Volatility Warrant Master Fund, Ltd. c/o Ogier Fiduciary Services (Cayman) Limited 89 Nexus Way, Camana Bay Grand Cayman KY1-9007 Cayman Islands Sabby Management, LLC 115 Hidden Hills Dr. Spicewood, TX 78669 Hal Mintz c/o Sabby Management, LLC 115 Hidden Hills Dr. Spicewood, TX 78669 (c). Citizenship: Sabby Volatility Warrant Master Fund, Ltd. - Cayman Islands Sabby Management, LLC - Delaware, USA Hal Mintz - USA (d). Title of class of securities: Common stock (the Common Stock) (e). CUSIP No.: 095633103 Item 3. If This Statement is filed pursuant to Section 240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a (a) [_] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) [_] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [_] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [_] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) [_] An investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E); (f) [_] An employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F); (g) [_] A parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G); (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813); (i) [_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [_] A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J); (k) [_] Group, in accordance with Section 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Item 4. Ownership. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: Sabby Volatility Warrant Master Fund, Ltd. - 177,513 Sabby Management, LLC - 177,513 Hal Mintz - 177,513 (b) Percent of class: Sabby Volatility Warrant Master Fund, Ltd. - 9.99% Sabby Management, LLC - 9.99% Hal Mintz - 9.99% ( (c) Number of shares as to which the person has: Sabby Volatility Warrant Master Fund, Ltd. ( (i) Sole power to vote or to direct the vote 0 , ( (ii) Shared power to vote or to direct the vote 177,513 , ( (iii) Sole power to dispose or to direct the disposition of 0 , ( (iv) Shared power to dispose or to direct the disposition of 177,513 . Sabby Management, LLC (i) Sole power to vote or to direct the vote 0 , ( (ii) Shared power to vote or to direct the vote 177,513 , ( (iii) Sole power to dispose or to direct the disposition of 0 , ( (iv) Shared power to dispose or to direct the disposition of 177,513 . Hal Mintz ( (i) Sole power to vote or to direct the vote 0 , ( (ii) Shared power to vote or to direct the vote 177,513 , ( (iii) Sole power to dispose or to direct the disposition of 0 , ( (iv) Shared power to dispose or to direct the disposition of 177,513 . As calculated in accordance with Rule 13d-3 of the Securities Exchange Act of 1934, as amended, (i) Sabby Volatility Warrant Master Fund, Ltd. beneficially owns 177,513 shares of the Issuer's common stock (Common Stock), representing approximately 9.99% of the Common Stock, and (ii) Sabby Management, LLC and Hal Mintz each beneficially own 177,513 shares of the Common Stock, representing approximately 9.99% of the Common Stock. Sabby Management, LLC and Hal Mintz do not directly own any shares of Common Stock, but each indirectly owns 177,513 shares of Common Stock. Sabby Management, LLC, a Delaware limited liability company, indirectly owns 177,513 shares of Common Stock because it serves as the investment manager of Sabby Volatility Warrant Master Fund, Ltd. Mr. Mintz indirectly owns 177,513 shares of Common Stock in his capacity as manager of Sabby Management, LLC. Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following []. ? Item 6. Ownership of More Than Five Percent on Behalf of Another Person. Not applicable Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. Not applicable Item 8. Identification and Classification of Members of the Group. Not applicable Item 9. Notice of Dissolution of Group. Not applicable ? Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. ? SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. January 3, 2024 (Date) Sabby Volatility Warrant Master Fund, Ltd. By: /s/ Harry Thompson Name: Harry Thompson Title: Authorized Person of TDF Management Ltd., a Director Sabby Management, LLC* By: /s/ Robert Grundstein Name: Robert Grundstein Title: Chief Operating Officer /s/ Hal Mintz* Hal Mintz *This Reporting Person disclaims beneficial ownership over the securities reported herein except to the extent of its pecuniary interest therein. The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature. Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent. Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001). EXHIBIT 1 ---------- JOINT FILING AGREEMENT The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stock of Bluejay Diagnostics, Inc is filed jointly, on behalf of each of them. Dated: January 3, 2024 Sabby Volatility Warrant Master Fund, Ltd. By: /s/ Harry Thompson Name: Harry Thompson Title: Authorized Person of TDF Management Ltd., a Director Sabby Management, LLC By: /s/ Robert Grundstein Name: Robert Grundstein Title: Chief Operating Officer /s/ Hal Mintz Hal Mintz
    Get the next $BJDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BJDX

    DatePrice TargetRatingAnalyst
    1/12/2022$10.00Buy
    Dawson James
    More analyst ratings

    $BJDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bluejay Diagnostics Provides Mid-Year Business and Corporate Update

      ACTON, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company developing rapid near-patient testing solutions for critical care, today provided a 2025 mid-year business and corporate update. Recent Business Highlights and Developments: SYMON Clinical Program Update: The Company has initiated its pivotal SYMON-II clinical study, following the successful completion of the SYMON-I pilot study, for which a primary analysis highlighted that IL-6 levels within 24 hours of ICU admission may predict sepsis patient mortality out to 28 days. Currently, the Company is collecting, freezing and biobanking samples, w

      6/3/25 4:05:00 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • Bluejay Announces Abstract Accepted for Presentation at the 2025 Society of Academic Emergency Medicine (SAEM) Annual Meeting

      ACTON, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX), today announced acceptance of an abstract related to the Symphony IL-6 Test, the company's lead product candidate, for presentation at the Society of Academic Emergency Medicine (SAEM) Annual Meeting, taking place in Philadelphia May 13-16, 2025. Results from SYMON-I, a pilot clinical study of interleukin-6 (IL-6) in sepsis patients intended or admitted for the intensive care unit (ICU), will be presented. SYMON-I evaluated IL-6 as a prognosticator for 28-day mortality and exploratory endpoints including 7-day mortality and microbiological positivity. "Early use of IL-6 in sepsis and septic shock pat

      4/15/25 7:00:00 AM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • Bluejay Diagnostics Announces Entry into Warrant Inducement Transaction for Approximately $3.7 Million in Gross Proceeds

      ACTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that it has entered into an agreement with institutional investors that are existing holders of warrants to purchase shares of common stock of the Company for cash (the "Existing Warrants"), wherein the investors agreed to exercise the Existing Warrants to purchase up 1,085,106 shares of common stock at a reduced exercise price of $3.42 per share, resulting in gross proceeds of approximately $3.7 million, before deducting

      4/7/25 5:21:14 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care

    $BJDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Dey Svetlana bought $1,535 worth of shares (500 units at $3.07), increasing direct ownership by 50% to 1,500 units (SEC Form 4)

      4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)

      12/14/23 4:17:42 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • Dey Indranil bought $1,635 worth of shares (500 units at $3.27), increasing direct ownership by 2% to 28,526 units (SEC Form 4)

      4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)

      12/14/23 4:16:33 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care

    $BJDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Dey Svetlana bought $1,535 worth of shares (500 units at $3.07), increasing direct ownership by 50% to 1,500 units (SEC Form 4)

      4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)

      12/14/23 4:17:42 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • Dey Indranil bought $1,635 worth of shares (500 units at $3.27), increasing direct ownership by 2% to 28,526 units (SEC Form 4)

      4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)

      12/14/23 4:16:33 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • SEC Form 3 filed by new insider Scally Frances P

      3 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)

      10/11/23 7:21:49 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care

    $BJDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Dawson James initiated coverage on Bluejay Diagnostics with a new price target

      Dawson James initiated coverage of Bluejay Diagnostics with a rating of Buy and set a new price target of $10.00

      1/12/22 9:00:51 AM ET
      $BJDX
      Medical/Dental Instruments
      Health Care

    $BJDX
    Leadership Updates

    Live Leadership Updates

    See more
    • Bluejay Diagnostics Appoints Edwin Rule as Vice President, Regulatory, Quality and Compliance

      ACTON, Mass., March 28, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay", "the Company") a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced that Edwin "Ed" E. Rule, has joined the Company as Vice President Regulatory, Quality and Compliance. He will report to Neil Dey, Chief Executive Officer. Mr. Rule is a highly credentialed regulatory, quality and compliance professional with more than 15 years of industry experience. He has extensive training and expertise in medical device regulations in the U.S. and numerous international markets.

      3/28/22 7:00:00 AM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • Bluejay Diagnostics, Inc. Appoints Mark Feinberg, M.D. as Chief Medical Advisor

      ACTON, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay") a late-stage, pre-revenue diagnostics/medical device company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced the appointment of Mark W. Feinberg, M.D. as Chief Medical Advisor. Dr. Feinberg will guide Bluejay's clinical development programs and provide strategic medical and scientific leadership to the Company. "I am very pleased to welcome Mark on board as Chief Medical Advisor. I believe Mark's expansive clinical background and strategic leadership skills will be invaluable as we seek to develop the Compa

      1/5/22 8:15:00 AM ET
      $BJDX
      Medical/Dental Instruments
      Health Care

    $BJDX
    SEC Filings

    See more
    • Bluejay Diagnostics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)

      5/28/25 5:18:49 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14A filed by Bluejay Diagnostics Inc.

      DEF 14A - Bluejay Diagnostics, Inc. (0001704287) (Filer)

      5/16/25 5:00:34 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Bluejay Diagnostics Inc.

      10-Q - Bluejay Diagnostics, Inc. (0001704287) (Filer)

      5/13/25 4:01:45 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care

    $BJDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Bluejay Diagnostics Inc.

      SC 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)

      11/14/24 5:49:49 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Bluejay Diagnostics Inc.

      SC 13G/A - Bluejay Diagnostics, Inc. (0001704287) (Subject)

      11/14/24 3:54:54 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Bluejay Diagnostics Inc.

      SC 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)

      7/3/24 4:01:01 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care